# Shanghai Juncell Therapeutics

Source: https://onco.cc/companies/shanghai-juncell-therapeutics/  
OnCo record `shanghai-juncell-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shanghai Juncell Therapeutics is a China-based cell therapy company running 2 late-stage cancer trials of GC101 TIL in melanoma and non-small-cell lung cancer.

## Summary

Shanghai Juncell Therapeutics, based in Shanghai, China, is a cell therapy company. Juncell Therapeutics is a biotech enterprise focused on research, development and commercialisation of innovative cell therapies for solid tumours, using tumour-infiltrating lymphocyte (TIL) technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GC101 TIL in melanoma and non-small-cell lung cancer. The largest, NCT06703398 (A Study of GC101 TIL in Advanced Melanoma), plans to enrol 98 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: cell-therapy
- Website: https://www.juncell.com/

## Sources

- Official website: https://www.juncell.com/
- ClinicalTrials.gov: trials led by Shanghai Juncell Therapeutics: https://clinicaltrials.gov/search?lead=Shanghai%20Juncell%20Therapeutics

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [GC101 TIL](https://onco.cc/drugs/gc101-til/)
- trials: [A Phase II Study of GC101 in NSCLC](https://onco.cc/trials/nct07560111/), [A Study of GC101 TIL in Advanced Melanoma](https://onco.cc/trials/nct06703398/)

---
JSON: https://onco.cc/api/v1/entities/shanghai-juncell-therapeutics.json